NCT06322862

Brief Summary

This is a prospective, multicentre, non-randomized cohort study using real-time intraoperative visualization of bowel perfusion by indocyanine green (ICG) in all-cause bowel ischemia. At intraoperative finding of bowel ischemia, the initial intraoperative plan is noted and resection margins marked with a steril pen. A fluorescence angiography will be performed and the surgeon will note whether the suspected ischemic bowel is perfused, whether there is a change in the resection margins in centimeters, and if the intraoperative plan has changed. If resection is indicated and the strategy of choice is an anastomosis, a renewed fluorescence angiography will be performed to assess anastomotic perfusion.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
9mo left

Started Mar 2024

Typical duration for not_applicable

Geographic Reach
1 country

5 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress75%
Mar 2024Feb 2027

Study Start

First participant enrolled

March 5, 2024

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

March 8, 2024

Completed
13 days until next milestone

First Posted

Study publicly available on registry

March 21, 2024

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2027

Last Updated

November 15, 2024

Status Verified

November 1, 2024

Enrollment Period

2.7 years

First QC Date

March 8, 2024

Last Update Submit

November 13, 2024

Conditions

Keywords

indocyanine greenperfusion assessmentacute care surgery

Outcome Measures

Primary Outcomes (1)

  • Change of strategy

    Change of intraoperative strategy due to ICG fluorescence angiography. Intraoperatively, a nurse will record the initial strategy, indication of resection in centimeters, before and after ICG angiography, and note whether there has been a change in strategy, and how.

    Assessed at day 30 and 90 after surgery

Secondary Outcomes (8)

  • Anastomosis

    Assessed at day 30 and 90 after surgery

  • Quantification using q-ICG

    30 months

  • Stomas

    Assessed at day 30 and 90 after surgery

  • Second-look

    Assessed at day 30 and 90 after surgery

  • Anastomotic leaks

    Assessed at day 30 and 90 after surgery

  • +3 more secondary outcomes

Study Arms (1)

single arm

OTHER
Other: Indocyanine green

Interventions

Intraoperative perfusion assessment with ICG Fluorescence Angiography (ICG-FA) in standard approved doses

single arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients \>18 years of age
  • Acute physiologic derangement and suspected of having bowel ischemia
  • Intraoperative finding of all-cause bowel ischemia with subsequent acute physiologic derangement

You may not qualify if:

  • Allergy toward; iodine, indocyanine green, or shellfish
  • Liver insufficiency
  • Thyrotoxicosis
  • Pregnancy or lactation
  • Permanently legally incompetent for any reason

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Department of Organ Surgery and Transplantation

Copenhagen, Capital Region, 2100, Denmark

RECRUITING

Department of Surgery, Bispebjerg Hospital

Bispebjerg, Denmark

RECRUITING

Department of Surgery, Herlev Hospital

Herlev, Denmark

RECRUITING

Department of Surgery, Nordsjællands Hospital

Hillerød, Denmark

RECRUITING

Department of Surgery, Hvidovre Hospital

Hvidovre, Denmark

RECRUITING

MeSH Terms

Conditions

Ischemia

Interventions

Indocyanine Green

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

IndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Sermed Ellebæk Nicolae, MD, PhDstudent

    Rigshospitalet, Denmark

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Sermed Ellebæk Nicolae, MD, PhD-student

CONTACT

Michael Patrick Achiam, MD, PhD, DMSc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, MD, PhD, DMSc

Study Record Dates

First Submitted

March 8, 2024

First Posted

March 21, 2024

Study Start

March 5, 2024

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

February 1, 2027

Last Updated

November 15, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share

Locations